Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
NCT00620074
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.
Patients with invasive aspergillosis for more than 30 days at the time of study entry.
Patients with uncontrolled bacterial or viral infection at the time of study entry.
Patients with significant liver dysfunction or who are taking certain medications which
interact with voriconazole.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Birmingham, Alabama
- Little Rock, Arkansas
- La Jolla, California
- LaJolla, California
- San Diego, California
- San Francisco, California
- Gainesville, Florida
- Miami, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Detroit, Michigan
- Detroit, Michigan
- Rochester, New York
- Chapel Hill, North Carolina
- Winston-Salem, North Carolina
- Portland, Oregon
- Philadelphia, Pennsylvania
- Houston, Texas
- Seattle, Washington
- Seattle, Washington
- Westmead, New South Wales
- Herston, Queensland
- Adelaide, South Australia
- Brugge,
- Bruxelles,
- Leuven,
- Yvoir,
- Curitiba, PR
- Rio de Janeiro, RJ
- Porto Alegre, RS
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Hamilton, Ontario
- Hamilton, Ontario
- Montreal, Quebec
- Quebec,
- Praha 2,
- Nantes, Cedex 01
- Marseille, Cedex 09
- Brest,
- Creteil,
- GRENOBLE Cedex 09,
- Paris,
- Rouen Cedex,
- Strasbourg,
- Berlin,
- Berlin,
- Bremen,
- Dresden,
- Frankfurt (Oder),
- Hamburg,
- Heidelberg,
- Homburg/Saar,
- Koeln,
- Mainz,
- Muenchen,
- Wuerzburg,
- Thessaloniki,
- Pune, Maharashtra
- Cuneo,
- Genova,
- Milano,
- Milano,
- Perugia,
- Pescara,
- Roma,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- RC Leiden,
- Lima,
- Gdansk,
- Warszawa,
- Lisboa,
- Lisboa,
- Moscow,
- Moscow,
- Moscow,
- Saint Petersburg,
- Singapore,
- Singapore,
- Badalona, Barcelona
- Madrid,
- Madrid,
- Salamanca,
- Valencia,
- Valencia,
- Geneve 14,
- Lausanne,
- Kuei-Shan Hsiang, Taoyuan County
- Kaohsiung,
- Taipei,
- Bangkok,
- Bangkok,
- Bangkok,
- Adana,
- Ankara,
- London,
- Manchester,
- Atlanta, Georgia
- Detroit, Michigan
- Fort Worth, Texas
- Fort Worth, Texas
- Nantes, Cedex
- Angers Cedex,
- Bobigny,
- Brest Cedex,
- Bris Sous Forges,
- Caen Cedex,
- Dinan Cedex,
- Grenoble Cedex 09,
- Lille Cedex,
- Lyon Cedex,
- Montpellier Cedex 5,
- Paris Cedex 18,
- Paris Cedex 20,
- Paris,
- Poitiers Cedex,
- Reims Cedex,
- Rouen Cedex,
- Suresnes,
- King of Prussia, Pennsylvania
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) | |||
Official Title ICMJE | Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment | |||
Brief Summary | This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy. | |||
Detailed Description | The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the study prior to January 12, 2009 were allowed to remain in the study until completing their participation as specified in the protocol. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Aspergillosis | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 6 | |||
Original Estimated Enrollment ICMJE | 50 | |||
Actual Study Completion Date ICMJE | February 2009 | |||
Actual Primary Completion Date | February 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy. Exclusion Criteria: Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole. | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | Canada | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00620074 | |||
Other Study ID Numbers ICMJE | A8851014 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |